The AAVCOVID vaccine program, a novel gene-based vaccine strategy led by Luk Vandenberghe, PhD, Associate Professor of Ophthalmology at Harvard Medical School and Director of the Grousbeck Gene Therapy Center at Mass Eye and Ear, that utilizes an adeno-associated virus (AAV) vector, was granted an award of $2.1 million from the Bill & Melinda Gates Foundation.... Read more about Preclinical Data on Single-Dose, Room Temperature-Stable COVID-19 Vaccine Supported by New Funding
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types—the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors–or vehicles—that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.... Read more about Researchers Uncover Mechanism for How Common Gene Therapy Vectors Enter Cells
In Nature, Luk Vandenberghe, PhD, Harvard Medical School Associate Professor of Ophthalmology and Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear, discusses increasing the efficiency of gene therapies by manipulating the viral vectors that transport genes into cells. He also talks about taking a nonprofit approach to tackle the economics of developing gene therapy for rare diseases.... Read more about Luk Vandenberghe, PhD, Builds Designer Viruses for Improved Gene Therapy
Luk H. Vandenberghe, PhD, along with collaborator and lead author Rob Collin, PhD, of Radboud University Medical Center, has been selected to receive the 2017 Ed Gollob Board of Directors’ Awardfrom the Foundation Fighting Blindness (FFB). This award is presented annually in recognition of significant research advancements. According to the FFB, their winning paper, “In vitro and in vivo rescue of aberrant splicing in CEP290-...
Boston, Mass. — Luk H. Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and an Assistant Professor of Ophthalmology at Harvard Medical School, has been awarded a Nelson Trust Award for Retinitis Pigmentosa by Research to Prevent Blindness (RPB) in the amount of $100,000 over two years. The Nelson Trust Award was established to stimulate, strengthen and accelerate research to improve...
